A Study to Evaluate the Effectiveness and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis
Brief description of study
AL (or light chain) amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down. These free light chains bind together to form amyloid fibrils that build up in the extracellular space of organs, affecting the kidneys, heart, liver, spleen, nervous system and digestive tract.
The primary purpose of this study is to determine if CAEL-101 improves the overall survival in Patients with cardiac AL Amyloidosis.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Amyloidosis
-
Age: Between 18 Years - 99 Years
-
Gender: All
Male or Female, 18 or older, AL amyloidosis Mayo stage IIIb
Updated on
09 Mar 2024.
Study ID: 843755
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
